Company: CMND
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005519
Chunk: 20

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: POS AM
Chunk 20
---
 of Financial Condition and Results of Operations” section and other financial information contained in
this prospectus.

|                                      |     | As of       
 October 31, 
 2024        |         |   |
|:-------------------------------------|:----|:------------|--------:|:--|
| U.S. dollars in thousands            |     |             |         |   |
| Cash                                 |     | $           |   6,574 |   |
| Warrant liability                    |     |             |  (3,520 | ) |
| Shareholders’ equity:                |     |             |         |   |
| Share capital                        |     |             |  24,168 |   |
| Warrant reserve                      |     |             |     459 |   |
| Share-based payment reserve          |     |             |   2,524 |   |
| Accumulated other comprehensive loss |     |             |     (21 | ) |
| Deficit                              |     |             | (23,929 | ) |
| Total shareholders’ equity           |     |             |   3,201 |   |
| Total capitalization                 |     |             |   3,201 |   |

Unless
otherwise indicated, the number of common shares outstanding prior to and after this offering
is based on 4,265,186 Common Shares outstanding as of October 31, 2024. The number of
Common Shares referred to above to be outstanding after this offering and, unless otherwise
indicated, the other information in this prospectus, excludes as of such date:

| ● | 310,388                                                                                 
 common shares that were issued as a result of the exercise of warrants after such date; |

| ● | 2,238,923 common shares issuable upon the exercise of warrants outstanding as of such date, at exercise prices ranging from        
 $1.0777 to $1,293.48, all of which were vested as of such date;                                                                    |
| ● | 5,521 common shares issuable upon the exercise of                                                                                  
 options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average 
 exercise price of $432.38, of which 5,351 were vested as of such date; and                                                         |
| ● | 264,338 common shares issuable upon the exercise of restricted share units issued to consultants under consulting agreements.      |

<div align='center'>9

SELLING SHAREHOLDERS